Skip to main
ALT
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc is poised for a positive outlook due to the significant efficacy demonstrated by pemvidutide in reducing liver fat, as evidenced by the MASLD trial, which reported up to 76% liver fat reduction and prominent improvements in key biomarkers associated with hepatic inflammation and fibrosis progression. The favorable tolerability profile of pemvidutide compared to other therapies enhances its attractiveness in the treatment landscape for obesity and metabolic diseases, particularly as it targets conditions like alcoholic liver disease (ALD) and metabolic-associated steatohepatitis (MASH). Furthermore, the company's strategic focus on leveraging pemvidutide's unique dual mechanism of action alongside the FDA's openness to non-invasive endpoints highlights potential pathways for expedited regulatory approval, maintaining high expectations for upcoming trial results.

Bears say

Altimmune's outlook is negatively impacted by the significant clinical development risks associated with pemvidutide, particularly as it competes with existing therapies that have proven to be suboptimal in efficacy and tolerability, despite some patient weight loss successes. Additionally, the company faces challenges related to commercialization, pricing, and reimbursement, heightening the overall risk profile for potential market adoption. Furthermore, external factors such as ongoing global uncertainties, including COVID-19 and regional conflicts, add layers of complexity that could disrupt clinical trials and future prospects.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Sep 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.